Assessment (MOCA) and concluded that MOCA performs much better than MMSE for cognitive impairment correct diagnosis.4 Objectives: To determine the prevalence of CD in SLE patients and compare MMSE and MOCA diagnosis effectiveness. Methods: All patients with at least 18 years old that met ACR/EULAR 2012 SLE classification criteria were included. Patients with associated comorbidity, not SLE related, that could alter cognitive functions, were excluded. 55 patients that fulfilled the inclusion criteria were admitted to Hospital Docente Padre Billini's rheumatology department from March to April 2016. After obtaining written consent, the psychology department applied both tests, MMSE and MOCA. A standardized form registered demographic variables. Data was analyzed using Microsoft Excel 2013. Results: 94.5% of the patients were women, 53% were between 31-45 years old, 52.7% were mulatto ethnic, 34.5% had at least a high school degree, 27.2% were diagnosed 1 year before enrollment, 60% had a low activity score using SLEDAI (<4), hypertension was the most common comorbidity with a 38.1%, 90.9% were taking corticoids, 80% were on antimalarial drugs (6 abandoned treatment, 2 by eye involvement, 1 allergic reaction, 2 were diagnosed with SLE the interview day), the most frequent neuropsychiatric symptom ever presented was convulsion (7.2%). Using MMSE 25.4% of the patients showed CD, however after adjusting the results according to the educational level, the percentage increased to 41.8%. MOCA classified that 67.2% of the patients had CD, of which 13 patients were MMSS positive, and finally, 22 classified after the score adjustment.
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Background: Primary antiphospholipid syndrome (PAPS) is characterized by venous and arterial thrombosis, obstetric morbidity and the presence of antiphospholipid antibodies. The utility of nailfold videocapillaroscopy in conditions such as scleroderma (SSc) and primary Raynaud's phenomenon is well known. Whether patients with PAPS have specific findings in nailfold videocapillaroscopy is not well stablished. Objectives: To evaluate findings on nailfold videocapillaroscopy in patients with PAPS and their association with clinical and serological features. Methods: We prospectively included 26 PAPS patients according to the modified Sidney criteria and the Alarcón-Segovia criteria for haematologic antiphospholipid syndrome, who regularly attend a tertiary referral center in Mexico City, and 15 healthy controls. We performed nailfold videocapillaroscopy according to the Cutolo technique (Optilia 200x) and obtained: capillary morphology, nonspecific abnormalities (tortuosity, crossed and dilated capillaries, capillary haemorrhages, neo-angiogenesis) and mean vascular density on 32 images per patient. We collected demographic, clinical (thrombosis, obstetric morbidity, non-criteria manifestations and comorbidities), serological (anticardiolipin antibodies, anti-β2 glycoprotein 1 antibodies and lupus anticoagulant) and treatment information. Analysis was performed used SSPS v.22, Chi square test was used to compare frequencies and Student's t test was used to compare means. Results: PAPS patients had higher frequency of at least 1 abnormal finding on videocapillaroscopy (77% vs 12%, p<0.009, OR=23, 95% CI=4-132), higher frequency of enlarged capillaries (69% vs 0%, p=0.0001, OR=33, 95% CI=3.8-295), lower frequency of "perfect normal" pattern (11.5% vs 56%, p=0.004, OR=0.1, 95% CI=0.02-0.48) than controls, and 8 patients (31%) showed changes compatible with the "early" SSc Cutolo pattern (<4 dilated capillaries/mm, <4 haemorrhages/mm, preserved architecture and no avascular areas). In PAPS patients, capillary haemorrhages were associated to neurologic manifestations (75% vs 14%, p=0.02, OR=19, 95% CI=1.4-248) and to comorbidity with hypertension (75% vs 14%, p=0.02, OR=19, 95% CI=1.4-248). Conclusions: PAPS patients frequently show at least one abnormality on videocapillaroscopy. The most frequent abnormalities are enlarged capillaries, microhaemorrhages and the presence of an "atypical normal" pattern. Capillary haemorrages are frequently found in patients with neurologic involvement of PAPS. The coexistence of hypertension or other comorbidities may contribute to the development of capillary abnormalities in PAPS patients. Background: Systemic lupus erythematous (SLE) is an autoimmune disease characterized by immune system disruption with autoantibodies production. One of the upregulated autoantibodies is the specific to the Ro antigen, a ribonucleoprotein associated to a small RNA, constituted by the 52KDa and 60 KDa polypeptides, whose epitopes are mainly conformational. The routine detection method for anti-Ro is an enzyme immunoassay, however, is possible to obtain false-negatives for anti-Ro and this could be avoided by analyzing both subunits separately. Objectives: To identify false-negatives for anti-Ro by analyzing both 52KDa and 60 KDa subunits separately, as well as to characterize if there are clinical or molecular differences in this subgroup of patients compared to anti-Ro negative cases. Methods: A cross-sectional, observational study of patients diagnosed of SLE according to SLICC 2012 criteria was performed. In these patients a complete blood-test was made, and clinical data by personal interview was collected. INF1A, Anti-Ro, anti-Ro52KDa and anti-Ro60KDa levels where measured by colorimetric methods. Biostatistical analysis was performed with R 3.3.2. Results: We selected 69 SLE patients with negative results for anti-Ro (2.34±4.17 U/mL) out of 142 total SLE patients. A total of 51 patients were negative for both anti-Ro subunits and 18 cases presented positive results (up to 20 pg/mL) for at least one of them. The subgroup of patients that exhibit simultaneously high levels of anti-Ro52KDa and anti-Ro60KDa have higher clinical activity compared to negative anti-Ro cases (75% of active patients against 41.2% in anti-Ro negative patients). However, no differences in the accumulated damage evaluated by SLICC score between negative anti-Ro cases and patients with at least one positive subunit were observed. We analyze serum levels of INF1A cytokine in the four groups of patients, and anti-Ro and subunits negative cases showed significant lower INF1A levels than the other patients (8.26±14.87 pg/mL and 26.62±40.71 pg/mL respectively; P=0.04). In addition, patients with high levels of antiRo52KDa subunit are those with the highest INF1A levels (anti-Ro 52+/anti-Ro60-23.5±47.6pg/mL of INF1A; anti-Ro 52+/anti-Ro60+ 36.4±37.9pg/mL of INF1A). Conclusions: In our anti-Ro seronegative patients, a 26% of false-negative cases were detected. These cases with high levels of almost one anti-Ro subunit showed significantly higher levels of INF1A in contrast to negative cases, supporting the fact that they are indeed a different group from the negative cases. Moreover, the high INF1A levels could be the reason of the observed differences in the clinical activity measured by SLEDAI score in both groups. Background: Systemic lupus erythematosus (SLE) is increasingly being diagnosed in our country. Despite the increasing number of patients, there are no studies describing their clinical profile at the time of diagnosis at the National Kidney and Transplant Institute (NKTI). This study aims to describe patients' initial clinical presentations, outcomes, and their survival rate within ten years. Objectives: To determine the ten-year survival rate and presenting clinical manifestations of Filipino patients first diagnosed with SLE at the National Kidney and Transplant Institute (NKTI) Methods: This is a retrospective cohort study using chart review of patients first diagnosed with SLE in 2004 followed up in the next ten years.
